[Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder].
BACKGROUND
Our aim was to evaluate treatment safety, tolerability, efficacy and compliance of long-acting injectable risperidone (LAIR) as maintenance treatment in a bipolar and schizoaffective inpatients sample with torpid course due to poor compliance to oral therapy.


METHODS
22 inpatients, 14 with a diagnosis of bipolar disorder and 8 with a diagnosis of schizoaffective disorder, were included in this study. They were treated with LAIR, 1 dose every 14 days, and were evaluated for 40 weeks with the Young Mania Rating Scale (YMRS), Hamilton Scale for Depression (HAM-D), UKU-Side Effect Rating Scale and Clinical Global Impression Severity of Illness scales (CGI).


RESULTS
Average YMRS scores were reduced significantly from 10.5 at baseline interview to 2.5 at week 40 (p < 0.001). HAM-D and UKU scales did not reach a statistically significant reduction. CGI-S scores were reduced from 3.8 at baseline to 1.5 at week 40 (p < 0.001).


CONCLUSIONS
LAIR could be an effective maintenance therapy for bipolar and schizoaffective patients with poor compliance to oral treatment.
Benabarre
A
A
Institut Clinic de Neurociències, Hospital Clinic de Barcelona, Universitat de Barcelona, IDIBAPS CIBER-SAM, Barcelona. 31555abh@comb.es
Castro
P
P
Sánchez-Moreno
J
J
Martínez-Arán
A
A
Salamero
M
M
Murru
A
A
Franco
C
C
Vieta
E
E
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D011618:Psychotic Disorders / Q000188:drug therapy*; D018967:Risperidone / Q000627:therapeutic use*; D055815:Young Adult
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D018967:Risperidone